On the stock market since 2011, it operates in the world of money and finance. Now — the numbers.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
It pays out $1.26 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, CURE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CURE is a high-risk stock — not yet profitable, and its future rides on its product catching on.